A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
Public ClinicalTrials.gov record NCT00359788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.
Study identification
- NCT ID
- NCT00359788
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 349 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2006 (Type not available)
- Primary completion
- Apr 2008 (Actual)
- Completion
- Not listed
- Last update posted
- May 16, 2014
Started 2006
United States locations
- U.S. sites
- 31
- U.S. states
- 25
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.325.904 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.325.925 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 205.325.909 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 205.325.912 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 205.325.911 Boehringer Ingelheim Investigational Site | Palo Alto | California | — | — |
| 205.325.935 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 205.325.903 Boehringer Ingelheim Investigational Site | West Haven | Connecticut | — | — |
| 205.325.905 Boehringer Ingelheim Investigational Site | Bay Pines | Florida | — | — |
| 205.325.922 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 205.325.907 Boehringer Ingelheim Investigational Site | North Chicago | Illinois | — | — |
| 205.325.928 Boehringer Ingelheim Investigational Site | Indiananapolis | Indiana | — | — |
| 205.325.923 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 205.325.902 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.325.908 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 205.325.920 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 205.325.932 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 205.325.915 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 205.325.914 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 205.325.910 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 205.325.924 Boehringer Ingelheim Investigational Site | East Orange | New Jersey | — | — |
| 205.325.921 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 205.325.917 Boehringer Ingelheim Investigational Site | Buffalo | New York | — | — |
| 205.325.926 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.325.901 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 205.325.931 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 205.325.929 Boehringer Ingelheim Investigational Site | Providence | Rhode Island | — | — |
| 205.325.936 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 205.325.918 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 205.325.927 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 205.325.919 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 205.325.906 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00359788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2014 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00359788 live on ClinicalTrials.gov.